| Residential College | false |
| Status | 已發表Published |
| A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells | |
Zhizhen Chen1 ; Jie Liu1; Dafeng Chu2; Yaming Shan3; Guixing Ma4; Hongmin Zhang4; Xiaohua Douglas Zhang1 ; Pu Wang5; Qiang Chen1; Chuxia Deng1; Weizao Chen6; Dimiter Dimitrov7; Qi Zhao1
| |
| 2018 | |
| Source Publication | International Journal of Biological Sciences
 |
| ISSN | 1449-2288 |
| Volume | 14Issue:7Pages:799–806 |
| Abstract | The insulin-like growth factors (IGFs), IGF-I and IGF-II, are essential for regulating cell growth, differentiation and metastasis of a broad range of malignancies. The IGF-I/II actions are mediated through the IGF receptor type 1 (IGF-1R) and the insulin receptor (IR), which are overexpressed in multiple types of tumors. Here, we have firstly identified a human engineered antibody domain (eAd) from a phage-displayed VH library. The eAd suppressed the signal transduction of IGF-1R mediated by exogenous IGF-I or IGF-II in breast cancer cell lines through neutralizing both IGF-I and IGF-II. It also significantly inhibited the growth of breast cancer cells. Therefore, the anti-IGF-I/II eAd offers an alternative approach to target both the IGF-1R signaling pathways through the inhibition of IGF-I/II. |
| Keyword | Insulin-like Growth Factor Yeast Display Affinity Maturation Ead |
| DOI | 10.7150/ijbs.25928 |
| Indexed By | SCIE |
| Language | 英語English |
| WOS Research Area | Biochemistry & Molecular Biology ; Life Sciences & Biomedicine - Other Topics |
| WOS Subject | Biochemistry & Molecular Biology ; Biology |
| WOS ID | WOS:000433261800011 |
| Scopus ID | 2-s2.0-85048170274 |
| Fulltext Access | |
| Citation statistics | |
| Document Type | Journal article |
| Collection | Faculty of Health Sciences DEPARTMENT OF BIOMEDICAL SCIENCES |
| Affiliation | 1.Faculty of Health Sciences, University of Macau, Macau, China 2.Department of Bioengineering, University of California, Los Angeles, California, USA. 3.National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, Jilin, China 4.Department of Biology, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment, SUSTech-HKU joint laboratories for matrix biology and diseases, Southern University of Science and Technology, Shenzhen, Guangdong, China 5.Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Guangdong, China 6.Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, Maryland, USA 7.Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pennsylvania, USA |
| First Author Affilication | Faculty of Health Sciences |
| Recommended Citation GB/T 7714 | Zhizhen Chen,Jie Liu,Dafeng Chu,et al. A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells[J]. International Journal of Biological Sciences, 2018, 14(7), 799–806. |
| APA | Zhizhen Chen., Jie Liu., Dafeng Chu., Yaming Shan., Guixing Ma., Hongmin Zhang., Xiaohua Douglas Zhang., Pu Wang., Qiang Chen., Chuxia Deng., Weizao Chen., Dimiter Dimitrov., & Qi Zhao (2018). A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells. International Journal of Biological Sciences, 14(7), 799–806. |
| MLA | Zhizhen Chen,et al."A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells".International Journal of Biological Sciences 14.7(2018):799–806. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment